Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

129

Address:

Ardelyx, Inc. 34175 Ardenwood Boulevard Fremont CA 94555 United States

Website:

Home

Phone:

510-745-1700

Leave a comment

Your email address will not be published. Required fields are marked *